TQB3122 / Sino Biopharm - LARVOL DELTA

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=86 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=86 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1 trial • Oncology • Solid Tumor

APPLICATION FOR CLINICAL TRIAL OF TQB3122 “PARP1 INHIBITOR” ACCEPTED BY NMPA (Sino Biopharm Press Release)

New trial • Solid Tumor